TOP CANCER HOSPITALS IN DENMARK AND NETHERLANDS FIRST IN EUROPE TO TREAT PATIENTS WITH RAPIDARC(TM) RADIOTHERAPY
COPENHAGEN, Denmark and AMSTERDAM, Netherlands, May 14
/PRNewswire-FirstCall/ -- Doctors in Denmark and the Netherlands have
successfully carried out Europe's first clinical treatments using advanced
RapidArc(TM) technology from Varian Medical Systems (NYSE: VAR). Cancer
patients at Copenhagen's Rigshospitalet and Amsterdam's VU University medical
center became the first people in Europe to benefit from this advanced form of
intensity-modulated radiotherapy (IMRT).
Dr. Svend Aage Engelholm, chief radiation oncologist of the Department of
Radiation Oncology at Copenhagen University Hospital (Rigshospitalet), says,
"Our first image guided RapidArc treatment went perfectly and the only unusual
aspect was that the patient joined the clinical team in a celebratory glass of
champagne after treatment. He was certainly aware that this was the first
clinical treatment of its kind in Europe." Dr. Engelholm said the actual
treatment took just 75 seconds to deliver.
The 60-year-old patient, who is half-way through his scheduled treatment
cycle, had been receiving five-field image-guided intensity-modulated
radiotherapy (IMRT) and doctors decided to convert his treatment plan to
RapidArc, which was commissioned on one of the hospital's Clinac(R) iX linear
accelerators earlier in the week. "We knew that we would really be able to
reduce the rectal dose to this patient by using RapidArc and, as it turned
out, we reduced it by 15 percent," adds Dr. Engelholm. He added that, as of
this week, RapidArc would be the hospital's standard treatment for all
prostate cancer patients and other suitable indications would follow.
Clinicians in Amsterdam also carried out their first RapidArc treatment on
a 59-year-old head/neck cancer patient. Dr. Ben Slotman, Professor and
Chairman, Department of Radiation Oncology, VU University medical center,
said, "As our patient was undergoing re-irradiation, it was important to
minimize doses to the brainstem and critical structures. We were able to
achieve an optimal plan quickly with RapidArc. We perform many IMRT
treatments and will replace all such treatments with RapidArc over time,
especially as treatment planning and dose verification only took 24 minutes,
which is considerably faster than with standard IMRT."
The treatment in Amsterdam took place on a Trilogy(R) linear accelerator
with advanced imaging using the machine's On-Board Imager(R) accessory.
Jiri Bocanek, Varian's senior product manager for delivery systems, said,
"We greatly appreciate the dedicated work of these two cancer centers to make
these fast and accurate treatments a reality. After more than a year of
evaluation, testing and quality assurance work, we are very happy to see a
smooth clinical introduction of RapidArc." He also paid tribute to the other
European members of the RapidArc Council -- CRLC Val d'Aurelle in Montpellier,
France and University Hospital in Zurich, Switzerland -- who are also soon to
start clinical treatments with RapidArc.
RapidArc delivers a complete volumetric intensity-modulated radiation
therapy treatment in a single arc of the treatment machine around the patient
and makes it possible to deliver advanced image-guided IMRT two to eight times
faster than is possible with conventional IMRT, including helical tomotherapy.
Treatment planning analyses show that RapidArc matches or exceeds the
precision of conventional IMRT systems and spares more of the healthy tissue
surrounding the tumor. Unrelated clinical studies on radiotherapy correlate
the ability to spare more healthy tissue with reduced complications and better
outcomes.
"RapidArc extends the versatility of Varian's image-guided radiotherapy
system, adding volumetric arc therapy to other advanced capabilities including
fixed-beam IMRT and stereotactic treatments," said Dow Wilson, president of
Varian's Oncology Systems business. "By outfitting their treatment machine
with this new capability, clinicians around the world have ensured that they
will be able to offer cancer patients the most appropriate form of treatment
according to each patient's specific needs."
Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's
leading manufacturer of medical devices and software for treating cancer and
other medical conditions with radiotherapy, radiosurgery, proton therapy, and
brachytherapy. The company supplies informatics software for managing
comprehensive cancer clinics, radiotherapy centers and medical oncology
practices. Varian is a premier supplier of tubes and digital detectors for
X-ray imaging in medical, scientific, and industrial applications and also
supplies X-ray imaging products for cargo screening and industrial inspection.
Varian Medical Systems employs approximately 4,600 people who are located at
manufacturing sites in North America and Europe and in its 60 sales and
support offices around the world. For more information, visit
http://www.varian.com/.
SOURCE Varian Medical Systems